08048035968
Premium Exporter of Genuine PEGASTA 6mg/0.6ml INJ  from India to Singapore – Orchard | Phoenix Exim

1. General Information

Pegasta 6 mg/0.6 mL Injection is a hematopoietic growth-factor medicine containing pegfilgrastim. It is generally used in patients receiving myelosuppressive chemotherapy who are at significant risk of febrile neutropenia. By increasing neutrophil production, it helps the body's immune system better protect against infections.

It is a prescription medicine and should be used only under the supervision of an oncologist or qualified healthcare professional.

2. Product Information

  • Brand Name: Pegasta
  • Generic Name: Pegfilgrastim
  • Strength: 6 mg/0.6 mL
  • Dosage Form: Injection
  • Category: Granulocyte Colony-Stimulating Factor (G-CSF)
  • Manufacturer: Intas Pharmaceuticals Ltd., India
  • Pack: Commonly supplied as a single 0.6 mL prefilled syringe
  • Storage: Refrigerate at 2°C–8°C; do not freeze.

3. Uses of Pegasta 6 mg/0.6 mL Injection

Pegasta is mainly used to:

  • Reduce the risk of infection associated with chemotherapy-induced neutropenia.
  • Reduce the incidence of febrile neutropenia in appropriate cancer patients receiving myelosuppressive chemotherapy.
  • Support recovery of neutrophil counts following chemotherapy.

4. Benefits of This Medicine

The main benefit of pegfilgrastim is its ability to stimulate the bone marrow to produce neutrophils, which are important white blood cells involved in fighting infections.

Potential benefits include:

  • Helps increase neutrophil levels after chemotherapy.
  • Helps reduce the risk of infection associated with severe neutropenia.
  • May reduce the likelihood of chemotherapy-related febrile neutropenia.
  • Its long-acting formulation generally allows administration once during a chemotherapy cycle when prescribed appropriately.

5. Side Effects of Pegasta

Possible side effects include:

  • Bone pain
  • Pain or discomfort at the injection site
  • Headache
  • Nausea
  • Muscle or joint aches
  • General body aches

Most side effects are manageable, but patients should inform their healthcare professional if symptoms are severe or persistent.

6. Common Side Effects

Commonly reported effects include:

  1. Bone pain
  2. Muscle pain
  3. Joint pain
  4. Headache
  5. Nausea
  6. Injection-site pain

Rare but potentially serious reactions can occur, including allergic reactions, splenic enlargement or rupture, acute respiratory distress, and kidney inflammation. Seek immediate medical attention for severe abdominal or left-shoulder pain, breathing difficulty, facial/throat swelling, or other serious symptoms.

7. How to Use Pegasta 6 mg/0.6 mL Injection

Pegasta should be administered subcutaneously by a healthcare professional or as specifically instructed by the treating healthcare team.

For adults receiving myelosuppressive chemotherapy, the usual labeled regimen for pegfilgrastim is one 6 mg subcutaneous injection once per chemotherapy cycle. It should not be administered within 14 days before or 24 hours after cytotoxic chemotherapy. The exact timing and regimen must be determined by the treating oncologist.

The product should remain refrigerated and should not be frozen. Inspect the solution before administration and do not use it if it is discolored or contains visible particles.

8. How Pegasta Works

Pegasta contains pegfilgrastim, a long-acting form of recombinant G-CSF.

After administration, pegfilgrastim stimulates receptors involved in the production and maturation of neutrophils in the bone marrow. This increases the number of circulating neutrophils, helping restore white blood-cell defenses following chemotherapy.

9. Safety Advice

  • Use only under medical supervision.
  • Tell your doctor about previous allergies to pegfilgrastim, filgrastim, or related medicines.
  • Inform your doctor if you have kidney problems, liver problems, heart disease, or a history of blood disorders.
  • Tell your healthcare provider about all medicines and supplements you are taking.
  • Do not freeze the injection.
  • Store at 2°C–8°C and protect it according to the product's storage instructions.
  • Do not use a damaged, discolored, or particulate-containing injection.
  • Seek urgent medical attention for breathing difficulty, severe allergic symptoms, severe abdominal/left-shoulder pain, or other unusual serious symptoms.
  • Pregnancy and breastfeeding should be discussed with a healthcare professional before treatment.

10. Frequently Asked Questions (FAQs)

Q1. What is Pegasta 6 mg/0.6 mL Injection?
Pegasta is a pegfilgrastim injection used mainly to reduce the risk of infection associated with chemotherapy-induced neutropenia.

Q2. What is the active ingredient in Pegasta?
The active ingredient is pegfilgrastim 6 mg in 0.6 mL.

Q3. Why is Pegasta given after chemotherapy?
Chemotherapy can reduce neutrophil levels. Pegfilgrastim stimulates bone marrow to produce more neutrophils, helping reduce the risk of infection.

Q4. How is Pegasta administered?
It is administered by subcutaneous injection, generally by a healthcare professional.

Q5. How should Pegasta be stored?
It should generally be stored refrigerated at 2°C–8°C and should not be frozen.

Q6. What is the most common side effect?
Bone pain is among the commonly reported side effects. Headache, nausea, injection-site pain, and muscle or joint aches may also occur.

Q7. Can Pegasta be taken without a prescription?
No. It is a prescription oncology-supportive medicine and should be used according to a healthcare professional's instructions.

Q8. Can Pegasta be used for every type of low white blood-cell count?
Not necessarily. The cause of neutropenia and the patient's treatment plan must be evaluated by a physician before pegfilgrastim is used.

11. Substitutes for Pegasta 6 mg/0.6 mL

Possible alternatives containing pegfilgrastim include products marketed under different brand names, such as Pegstim, Pegheal, PEGLAST, Peg-Grafeel, PEGEX, and other pegfilgrastim preparations. Availability and regulatory approval vary by country, and products should not be substituted without confirmation from a healthcare professional or pharmacist.

12. SEO Keywords

Primary Keywords:

  • Pegasta 6mg/0.6ml Injection
  • Pegasta 6mg Injection
  • Pegfilgrastim 6mg Injection
  • Pegfilgrastim 6mg/0.6ml
  • Pegasta Injection exporter
  • Pegfilgrastim Injection exporter from India
  • Pegasta 6mg supplier India
  • Pegasta 6mg pharmaceutical exporter
  • Pegfilgrastim oncology medicine exporter
  • Pegfilgrastim cancer supportive medicine

Long-Tail B2B Keywords:

  • Buy Pegasta 6mg/0.6ml Injection from India
  • Pegasta 6mg Injection pharmaceutical supplier from India
  • Pegfilgrastim 6mg/0.6ml Injection exporter from Nagpur India
  • Genuine Pegasta 6mg Injection supplier India
  • Pegasta 6mg Injection international pharmaceutical exporter
  • Pegfilgrastim 6mg Injection wholesale supplier India
  • Pegasta 6mg oncology medicine exporter from India
  • Pegfilgrastim Injection supplier for international buyers
  • Pegasta 6mg/0.6ml Injection bulk supplier
  • Pegfilgrastim 6mg Injection export supplier from India

Export-Focused Keywords:

  • Pegasta 6mg Injection exporter to USA
  • Pegasta 6mg Injection exporter to UK
  • Pegasta 6mg Injection exporter to Australia
  • Pegasta 6mg Injection exporter to Singapore
  • Pegasta 6mg Injection exporter to Canada
  • Pegasta 6mg Injection exporter to South Korea
  • Pegasta 6mg Injection exporter to UAE
  • Pegfilgrastim 6mg exporter from Nagpur India
  • Pegfilgrastim oncology medicines supplier India
  • Indian pharmaceutical exporter for Pegfilgrastim
Aug 20th, 2026 2:37 PM

Keywords